The FDA recently expanded its indication for use in the pre-chemotherapy setting after it elicited significant delays in disease progression and a strong trend for increased overall survival in phase III studies.
← all excerpts
Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.
1
—
—